Opinion

Video

AE Management for Combination Regimens in Advanced RCC

Author(s):

Martin H. Voss, MD,Moshe Ornstein, MD

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

  1. Please comment on dose reduction and treatment duration rates in the CLEAR study and real-world experience. (Motzer JCO 2024).
    1. What are the typical starting doses for lenvatinib and pembrolizumab in your practice?
    2. What is your approach to dose reductions and reverting to higher doses in your practice?
  2. What are some commonly observed adverse events with IO-TKI regimens?
    1. What strategies do you implement to mitigate and monitor for common side effects?
    2. What interventions help promote early AE detection and proactive mitigation?
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content